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Abstract
OBJECTIVE: To investigate the clinical effects of
Weining Granules on gastric precancerous lesions
(GPLs).
METHODS: 120 patients with GPLs were randomly
assigned in a 1:1 ratio to receive Weining Granules
(trial group) or the comparator Weifuchun tablets
(control group) for 6 months. Outcomes were com-
pared between the two groups including: overall
response; gastroscopically-determined response;
pathologically-confirmed response; eradication of
Helicobacter pylori (HP); microvessel density (MVD)
in the gastric mucosa; expression of vascular endo-
thelial growth factor (VEGF); interleukin 2 (IL-2); in-
terleukin 6 (IL-6); T lymphocyte subsets; immuno-
globulins; symptom scores; quality of life (QOL);
and adverse reactions.
RESULTS: Patients in the trial group had a signifi-
cantly higher (P<0.05) overall response rate (81.7%)
as compared with those in the control group
(63.3%). Relative to treatment with Weifuchun tab-
lets treatment with Weining Granules resulted in a
significant improvement (P<0.05) in the scores for
gastric pain, distension and stuffiness in the hypo-
chondrium, and anorexia. As compared with the
tablets the Granules were associated with a signifi-
cantly higher overall gastroscopically-determined
response rate (78.3% ; P<0.05). Pathological exami-
nation of tissue samples indicated that 61.7% of pa-
tients receiving the granules were cured with an
overall response rate of 75.5%; these rates were sig-
nificantly higher than in the control group (P<0.05).
In comparison with patients receiving the tablets,
those given the granules were significantly more
likely to have their HP eradicated (75.0% vs. 51.4%;
P<0.05). Improvements in MVD, VEGF, CD4 + , CD4 +/
CD8 + , IL-2, IL-6 and IgG were significantly greater
with the Weining Granules than with the Weifuc-
hun tablets (P<0.05 or P<0.01). After follow-up of 1
year, 17.5% of patients in the trial group relapsed
as compared with 39.5% in the control group (P<
0.05). Relative to the control group, the trial group
showed significantly greater improvements in phys-
ical, psychological and social relationships, and in
environmental domains (P<0.05 or P<0.01). No sig-
nificant adverse reactions were observed during
treatment.
CONCLUSION: The Weining Granules appear to be
effective in improving the gastric precancerous
state and the main symptoms, in inhibiting angio-
genesis, enhancing immune function and QOL, and
in reducing 1-year relapses. In addition, this prepa-
ration seems to be associated with a low risk of ad-
verse events, making it a safe and efficacious op-
164
JTCM |www. journaltcm. com June 15, 2012 |volume 32 | Issue 2 |
Deng X et al. A clinical study ofWeining granules in the treatment of gastric precancerous lesions
tion for the treatment of GPLs.
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INTRODUCTION
Worldwide, gastric carcinoma is the fourth most com-
mon type of cancer diagnosed each year and has the
second highest incidence and mortality rates of all ma-
lignancies[1]. Precancerous gastric lesions (GPLs) [2], of-
ten seen in patients with chronic atrophic gastritis
(CAG), represent a pathological state that includes in-
testinal metaplasia (IM) and dysplasia. GPLs are an im-
portant stage in the process of transformation from
normal gastric mucosa to gastric cancer. Effective treat-
ments for this condition are not currently available[3-5].
The present multi-center randomized controlled clini-
cal trial was designed to investigate the efficacy of the
Weining Granules in the treatment of GPLs.
METHODS
Subjects
We enrolled 120 outpatients and inpatients with gas-
troscopically and pathologically confirmed CAG and
concomitant IM or dysplasia who presented to the Rui-
kang Hospital of Guangxi Traditional Chinese Medical
University, the First Hospital of Guangxi Traditional
Chinese Medical University and the First Hospital of Ji-
angxi University of Traditional Chinese Medicine. The
patients were randomized in equal numbers (60 per
group) to receive the Weining Granules (trial group) or
the comparator Weifuchun Tablets (control group).
In the trial group, there were 40 males and 20 females
with a mean age of 49.2±4.2 years (range, 32-69 years)
and a mean disease duration of 7.5±5.6 years (range,
0.5-20 years). Gastric gland atrophy was found to be
mild in severity in 27 patients, moderate in 28 and seri-
ous in five. Concomitant IM or atypical hyperplasia
(ATP) alone was detected in 35 and 11 patients, respec-
tively. Twelve patients exhibited the coexistence of both
IM and ATP. There were 36 patients with moderate
IM and seven with serious IM. ATP was moderate in
15 subjects and serious in six. Forty patients (66.7%)
tested positive for Helicobacter pylori (HP).
The control group consisted of 45 men and 15 women
aged 35–68 years (mean, 46.7±3.5 years) who had suf-
fered from GPLs for 0.7 to 21 years (7.8 ±6.2 years).
The numbers of patients with mild, moderate or seri-
ous gastric gland atrophy were 28, 26 and 6, respective-
ly. IM or ATP was found separately in 34 and 12 pa-
tients, respectively and together in 13 patients. IM was
either moderate (n=34) or serious (n=6) in severity.
ATP was moderate in 16 cases and serious in six. HP
positivity was detected in 37 patients (61.7%).
Patients in the two groups were comparable with re-
spect to general information on sex, age, duration of
disease and severity of disease (P>0.05).
Diagnostic criteria
The diagnosis criteria used in this study were devel-
oped by referring to the following documents: the
Guidance for Clinical Research of New Traditional
Chinese Drugs[6]; the Classification of and Diagnostic
Criteria for Chronic Gastritis by Fiber Gastroscopy;
the Pathological Diagnostic Criteria for Atrophic Gas-
tritis[7]; and the Diagnostic, Syndrome Differentiation
and Response Criteria for Chronic Gastritis in Integrat-
ed Chinese and Western Medicine[8]. Symptoms and
signs that may lead to a diagnosis of CAG or GPLs in-
clude chronic recurrent periodic and/or rhythmic dull
pain; stuffiness and discomfort in the upper abdomen;
heartburn and acid regurgitation; and localized tender-
ness in the upper abdomen. Findings from auxiliary ex-
amination should include: mucosal erosion; congestion
and edema; red and white (mainly white) mucous
membranes and submucosal vessels on electronic gas-
troscopy; and GPLs confirmed by pathological exami-
nation of samples taken during gastroscopy within 1
week, with the presence of moderate to serious IM and
dysplasia.
Inclusion criteria
Patients eligible for entry were men or women aged be-
tween 18 and 70 years who met the diagnostic criteria
for GPLs described above and who signed the in-
formed consent f.
Exclusion criteria
Patients were excluded if they: 1) developed any com-
plications requiring surgery within 30 days before the
start of the study; 2) were women who were pregnant
or were planning pregnancy, or were current breastfeed-
ing mothers; 3) had a propensity for allergy or a histo-
ry of allergy to multiple drugs; 4) had serious primary
diseases involving important organs such as the heart,
brain, lungs, liver, kidneys or the hematopoietic sys-
tem; 5) suffered from alcoholism or other conditions
that may prevent them from participation; 6) had any
other complications or disorders that may interfere
with the conduct of the study; and 7) had participated
in any other clinical trials within the past month.
Drop-out criteria
Patients were considered to be drop-outs if they: initiat-
ed withdrawal from the study themselves; were lost to
follow-up; were requested to withdraw from the study
by the investigator because of poor compliance, occur-
rence of serious comorbidities or complications, or seri-
ous adverse events; had completed the study but the
dose they had taken was not in the range of 80% to
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120% of the expected dose; or gave away information
that affected study blinding or caused emergency un-
blinding.
Elimination criteria
Patients eliminated from the study were those who:
had a misdiagnosis; met the exclusion criteria; missed
one dose of treatment during study; had no test re-
cords; or could not be evaluated for response due to
the use of certain prohibited drugs.
Random binding
In a multicenter stratified randomized design, the Sta-
tistical Product and Service Solutions 13.0 package
from SPSS Inc. (Chicago, USA) was used to generate
seed numbers and random digits by which the drugs
were coded (the envelope method). Patients were ad-
ministered the compounds under evaluation according
to the sequence in which they entered the study.
Outcome measures
Quantitative Observation of Clinical Symptoms: Ac-
cording to the Guidance for Clinical Research of New
Traditional Chinese Drugs[6], individual symptoms
were scored as 0 (absent), 1 (mild), 2 (moderate) or 3
(serious) in severity. Response to treatment was deter-
mined by assessing changes in the scores for individual
symptoms.
Gastroscopic and Histopathological Investigation of
Precancerous Lesions: Gross gastric mucosa was ob-
served by means of gastroscopy in patients receiving ei-
ther of the two treatments. Tissue samples taken dur-
ing gastroscopy were pathologically examined for any
signs of reversal of IM and dysplasia.
Eradication of HP: Eradication of HP in patients treat-
ed with either regimen was assessed by histological ex-
amination and the 14C-urea breath test.
Angiogenesis: In this study, microvessel density
(MVD) and vascular endothelial growth factor
(VEGF) in tissues with mild superficial gastritis, GPLs
and gastric cancer were investigated immunohisto-
chemically. Regarding the examination of MVD, fluo-
rescence microscopy was used for the detection of VIII
factor-positive cells, and 10 high-power fields (× 400)
were randomly selected for calculation of the number
of microvessels. With respect to the detection of
VEGF, Weidner's method[9] was used, and a positive co-
efficient of 0-1 was classified as negative (-), 2-4 as
weakly positive (+ ), 5-8 as positive (++ ) and 9-12 as
strongly positive (+ + +).
Immune Function: Changes in interleukin 2 (IL-2), in-
terleukin 6 (IL-6), T lymphocyte subsets (CD3+, CD4+,
CD8 + , CD4 +/CD8 + ) and immunoglobulins (IgG, IgA
and IgM) were assessed.
Quality of Life: Quality of life (QOL) was evaluated us-
ing the short version of theWorld Health Organization
Quality of Life Assessment (WHOQOL-BREF) [10,11],
which consists of 26 items, four domains (i.e. physical
health, psychological health, social relationships and en-
vironment domains), and two items that are separately
examined. The items are scored within a range of 1-5.
Domain scores are scaled in a positive direction, i.e.
higher scores indicate better QOL.
Recurrence of Precancerous Lesions: Patients were fol-
lowed up for any relapses of precancerous lesions for 1
year after the completion of 6-months of treatment.
Response evaluation
Criteria for response evaluation were developed based
on the Guidance for Clinical Research of New Tradi-
tional Chinese Drugs[6].
Criteria for Evaluation of Overall Response: Clinical
Cure: Resolution of clinical symptoms and signs; signif-
icant improvement in the severity of chronic mucosal
inflammation to a mild level on repeat gastroscopy;
normalization or resolution of gland atrophy, IM and
dysplasia on pathohistological examination of tissues
taken during gastroscopy. Significant Response: Resolu-
tion of main symptoms and signs; improvement of
chronic mucosal inflammation on repeat gastroscopy;
and normalization or a decrease of two grades in the se-
verity of gland atrophy, IM and dysplasia on pathohis-
tological examination. Response: Significant alleviation
of main symptoms and signs and a decrease of more
than 50% in the size of mucosal lesions on repeat gas-
troscopy; a decrease of more than one grade in the se-
verity of chronic inflammation, gland atrophy, IM and
dysplasia on pathological examination. No Response:
Failure to meet the above criteria, or the occurrence of
exacerbation.
Criteria for Response Evaluation by Gastroscopy: Clini-
cal Cure: Significant improvement in the severity of
gastric mucosal inflammation, erosion, congestion and
edema to a mild level on repeat gastroscopy. Significant
Response: Improvement of gastric mucosal inflamma-
tion, erosion, congestion and edema on repeat gastros-
copy. Response: A decrease of more than 50% in the
size of gastric mucosal lesions on repeat gastroscopy.
No Response: No significant improvement in the gas-
tric mucosa (epiphase) as determined using gastrosco-
py. Criteria for Response Evaluation by Pathological
Examination of Samples Taken during Gastroscopy.
Clinical Cure: Normalization or resolution of gland at-
rophy, IM and dysplasia. Significant Response: A de-
crease of two grades in the severity of gland atrophy,
IM and dysplasia. Response: A decrease of more than
one grade in the severity of acute or chronic inflamma-
tion; alleviation in gland atrophy, IM or dysplasia
alone. No Response: Failure to achieve pathological im-
provement or the occurrence of exacerbation.
Criteria for Evaluation of HP Eradication: According
to the Consensus on Helicobacter pylori developed by
the Chinese Society of Gastroenterology, and the Chi-
nese Medical Association in 2003[12], patients were con-
sidered to have achieved HP eradication if results were
negative for the following: HP on histological examina-
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tion of Warthin-Starry silver-stained tissues taken from
the gastric antrum and body; and a 14C-urea breath test
at 4 weeks after the last dose of treatment.
Dosage and administration
Patients in the trial group received one sachet (15 g) of
the Weining Granules orally, which was prepared using
medicinal herbs such as Huang Qi (Radix Astragali),
Fu Ling (Poria), Jiang Huang (Rhizoma Curcumae
Longae) and Gou Qi (Fructus Lycii). This was a prod-
uct developed by Rui Kang Hospital, Guangxi Tradi-
tional Chinese Medical University (lot number:
20050806). It was taken once daily for two 3-month
courses. Patients in the control group received four
Weifuchun tablets prepared using medicinal herbs such
as Hong Shen (Red Ginseng), Xiang Cha Cai (Isodon),
Zhi Ke (Citrus Aurantium) and others (HuqingYu
Tang Pharmaceutical Co., Ltd., Hangzhou, Zhejiang,
China; lot number: 20090120) three times daily for
two 3-month courses.
During treatment, patients in both groups were re-
quired to discontinue any medications that could inter-
fere with the results of this study. In addition, patients
were educated to follow a regular diet schedule, to
avoid raw, cold, greasy or spicy food and to maintain a
good mood.
Ethics review
This clinical trial was reviewed and approved by the
Ethics Committee of Guangxi Traditional Chinese
Medical University and conducted in accordance with
the guidelines of the Good Clinical Practice (GCP) of
China[13] and the ethical standards laid down in the
Declaration of Helsinki[14]. All patients signed an in-
formed consent form prior to their inclusion in the
study.
Quality control
A clinical trial monitor was assigned to oversee the
whole trial process to ensure rigorousness and validity.
All participating staff received special training. In each
participating center, assessment of outcome measures
was conducted by a specialist using uniform tech-
niques. Evaluation of symptoms and QOL was under-
taken by a trained physician who interviewed patients
face-to-face to obtain objective information, without
using any suggestive words or phrases before they com-
pleted the questionnaire.
Statistical methods
The data obtained were processed using the Statistical
Product and Service Solutions 13.0 package SPSS, Chi-
cago, IL, USA) and analyzed using the chi-square test,
Student's t-test, rank-sum test, and Kruskal–Wallis
test.
RESULTS
Overall response
The overall proportion of responders (81.7% vs.
63.3%) who achieved a clinical cure (30 vs. 24), a sig-
nificant response (8 vs. 6) or a response (11 vs. 8) was
significantly higher in the trial group than in the con-
trol group (P<0.05). There were 11 and 22 patients
showing no response to the Weining Granules and the
Weifuchun tablets, respectively (Table 1).
Changes in scores of main symptoms
Scores of main symptoms were significantly decreased
after the administration of either treatment regimen
(P<0.05). Scores of gastric pain, distension and stuffi-
ness in the hypochondrium, and anorexia were signifi-
cantly better using the Weining Granules than using
the Weifuchun tablets (P<0.05; Table 2).
Response assessed using gastroscopy
Treatment with the Weining Granules was associated
with cure in 38 cases, a significant response in five cas-
es, a response in four cases and no response in 13 cases.
In contrast, treatment with the Weifuchun tablets was
associated with cure in 29 cases, a significant response
in three cases, a response in four cases and no response
in 24 cases. The overall response rate in the trial group
was significantly higher than that in the control group
(78.3% vs. 60.0%; P<0.05; Table 3).
Response assessed by pathological examination of
tissues taken during gastroscopy
According to the criteria for response evaluation by
means of pathological examination of tissues taken dur-
ing gastroscopy, cure was experienced in 37 patients, a
significant response in four, a response in four and no
response in 15 in the trial group. In the control group,
there was cure in 25 patients, a significant response in
three, a response in four and no response in 28. The
percentage of patients achieving cure of GPLs (61.7%
vs. 41.7%) and the overall proportion of patients who
met the response criteria (75.5% vs. 53.3%) were sig-
nificantly higher in the trial group as compared with
the control group (P<0.05; Table 4).
HP eradication
Of 40 patients who were positive for HP in the trial
group, 75.0% (30/40) were found to have had their
HP eradicated after treatment with the Weining Gran-
ules, as compared with 51.4% (9/37) in the control
group (P<0.05; Table 5).
Changes in MVD
Significant changes in MVD were observed after treat-
ment with the Weining Granules or the Weifuchun tab-
lets (P<0.01). Relative to the Weifuchun tablets, the
Weining Granules were associated with a significantly
greater decrease in MVD (P<0.01,Table 6).
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Table 1 Between-group comparison of response
Group
Trial group (60)
Control group (60)
Cure
30
24
Significant response
8
6
Response
11
8
No response
11
22
Overall response rates
81.7%*
63.3%
Note: *P<0.05, compared with the control group.
Table 2 Changes in scores for the main symptoms ( xˉ ±s)
Main symptoms
Gastric pain
Distension and stuffiness
in hypochondrium
Belching
Acid regurgitation
Anorexia
Nausea and vomiting
Trial group (n=60)
Before treatment
2.15±0.21
1.88±0.13
1.31±0.42
1.29±0.41
1.35±0.56
1.54±0.10
After treatment
1.11±0.32*△
0.96±0.27*△
0.68±0.19*
0.66±0.22*
0.69±0.26*△
0.98±0.26*
Control group (n=60)
Before treatment
2.01±0.11
1.87±0.19
1.35±0.17
1.33±0.11
1.29±0.23
1.46±0.02
1.28±0.28*
1.49±0.55*
0.72±0.26*
0.73±0.18*
0.66±0.39*
1.03±0.24*
After treatment
Notes: *P<0.05, compared with pre-treatment values; △P<0.05, compared with the control group.
Table 3 Response assessed using gastroscopy
Group
Trial group (60)
Control group (60)
Cure
38
29
Significant response
5
3
Response
4
4
No response
13
24
Overall response rates
78.3%*
60.0%
Notes: *P<0.05, compared with the control group.
Table 4 Response assessed by pathological examination of tissues taken during gastroscopy
Group
Trial group (60)
Control group (60)
Cure
37
25
Significant
response
4
3
Response
4
4
No Response
15
28
GPLs cure rates
61.7%*
41.7%
Overall
response rates
75.5%*
53.3%
Notes: *P<0.05, compared with the control group.
Table 5 HP Eradication
Group
Trial group
Control group
n
60
60
HP positivity
Before treatment
40
37
After treatment
10
18
Number of patients achieving HP
eradication (%)
30 (75.0%)*
19 (51.4%)
Notes:*P<0.05, versus the control group.
Table 6 Changes in MVD ( xˉ ±s)
Group
Trial group
Control group
n
60
60
MVD
Before treatment
57.68±5.54
57.92±6.75
After treatment
45.76±6.97**△△
49.78±7.43**
Notes: **P<0.01, compared with pre-treatment values; △△P<0.01, compared with the control group.
Changes in VEGF expression
Before treatment, VEGF expression varied from (-) to
(+) for a few patients and from (++) to (+++) for most
patients in both groups, suggesting the possible pres-
ence of microvascular proliferation in the gastric muco-
sa in most patients with GPLs. The positive coefficient
of VEGF expression was significantly decreased after
treatment with either regimen (P<0.05). When com-
paring VEGF expression between groups after treat-
ment no significant differences were found (P>0.05; Ta-
ble 7).
Changes in immune function
The Weining Granules were associated with significant
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changes in IL-2, IL-6, CD4+, CD4+/CD8+ and IgG (P<
0.05 or P<0.01). CD4 + , CD4 +/CD8 + , IL-2, IL-6, and
IgG were more significantly improved after treatment
with the Weining Granules than after treatment with
the Weifuchun tablets (P<0.05 or P<0.01; Table 8).
Changes in QOL
Significant increases in the physical and psychological
domain scores (P<0.01) and the social, environment
and total scores (P<0.05) were observed after dosing
with the Weining Granules. Similarly, the Weifuchun
tablets were also associated with significant increases
in the physical and psychological domain scores (P<
0.05). Comparison of QOL between groups found
that patients in the trial group experienced signifi-
cantly greater (P<0.05) improvements in the physical
and psychological domains relative to the control
group (Table 9).
Relapse
During follow-up of 40 patients whose GPLs were
cured by treatment with the Weining Granules, seven
(17.5%) experienced relapse. In contrast, among 38 pa-
tients followed up in the control group, 15 (39.5%) re-
ported recurrence. The difference reached statistical sig-
nificance (P<0.05,Table 10).
Adverse reactions
None of the 60 patients in the trial group reported any
significant adverse reactions during treatment. In con-
trast, 5% (3/60) of patients in the control group devel-
oped mild nausea which was tolerable and was sponta-
neously resolved without a need for treatment discon-
tinuation.
Table 7 Changes in VEGF expression
VEGF expression levels
-
+
++
+++
Trial group (n=60)
Before treatment
5
10
25
20
After treatment
18**
20
16
6
Control group (n=60)
Before treatment
6
11
22
21
16**
18
19
7
After treatment
Notes: **P<0.01, versus pre-dosing values within the same group.
Table 8 Changes in immune function ( xˉ ±s)
Parameters
IL-2
IL-6
CD3+
CD4+
CD8+
CD4+/CD8+
IgG
IgA
IgM
Trial group (n=60)
Before treatment
4.75±2.12
143.56±20.16
61.98±2.16
37.35±1.35
24.75±1.02
1.52±0.15
18.89±3.49
2.92±1.41
2.22±1.18
After treatment
5.52±1.52*△
108.05±22.15**△△
62.78±1.25
41.39±1.82*△
24.28±0.89
1.62±0.08*△
13.22±3.22**△△
2.82±1.33
1.98±1.25
Control group (n=60)
Before treatment
4.69±2.49
138.76±23.57
62.14±2.02
37.36±1.42
25.14±1.33
1.53±0.42
18.67±3.51
2.85±1.37
2.18±1.19
After treatment
5.18±1.52
128.56±21.26*
62.18±1.26
37.89±1.17
24.95±2.06
1.54±0.47
17.12±3.86*
2.83±1.57
2.19±0.92
Notes: *P<0.05, compared with pretreatment values within the same group; **P<0.01, compared with pretreatment values;△P<0.05,
compared with the control group after treatment; △△P<0.01, compared with the control group after treatment.
Table 9 Changes in QOL scores ( xˉ ±s)
Domains
Physical health
Psychological
Social relationships
Environment
Total scores
Trial group (n=60)
Before treatment
13.56±2.36
13.46±2.49
15.28±2.20
12.47±2.06
58.75±10.35
After treatment
22.78±2.36**△
20.57±2.58**△
19.79±2.16*
17.68±2.37*
75.86±9.84*
Control group (n=60)
Before treatment
13.76±2.35
12.85±2.58
14.97±2.23
13.32±2.43
56.42±11.46
After treatment
19.31±1.58*
16.84±2.24*
19.86±2.46*
18.26±2.24*
68.36±10.47*
Notes: *P<0.05, compared with the pre-treatment values; **P<0.01, compared with the pre-treatment values;△P<0.05, compared with the
control group.
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Table 10 Relapse rates
Group
Trial group (60)
Control group (60)
Number of
patients followed
up
40
38
Number of
patients
experiencing
relapse (%)
7 (17.5%)*
15 (39.5%)
Notes: *P<0.05, compared with the control group after
treatment.
DISCUSSION
In traditional Chinese medicine (TCM), there seems
to be no equivalent term for GPLs. From the perspec-
tive of TCM based on the clinical symptoms of gastric
pain, distension and stuffiness in the hypochondrium,
and anorexia, GPLs may be caused by Qi deficiency in
the spleen and stomach, and blood stasis in the stom-
ach collateral. Therefore, treatment of GPLs should fo-
cus on fortification of the spleen, replenishment of Qi
and resolution of stasis[15-18].
The Weining Granules were prepared using medicinal
herbs such as Huang Qi (Radix Astragali), Fu Ling (Po-
ria), Jiang Huang (Rhizoma Curcumae Longae) and
Gou Qi (Fructus Lycii). This preparation has
spleen-fortifying, Qi-replenishing, blood-activating
and stasis-resolving effects. Huang Qi (Radix Astragali)
and Jiang Huang (Rhizoma Curcumae Longae) have
been found to be associated with increased anti-tumor
activity in dendritic cells, enhanced immune response
in the tumor-bearing host and significant inhibitory ef-
fects on tumors[19,20]. Our previous study also found
that treatment of the human gastric cancer cell line
SGC-7910 with Weining Granules was associated with
proliferation and apoptosis, inhibition of adhesion to
laminin, suppression of cell motility and invasiveness,
and decreased levels of matrix metalloproteinase-2 and
matrix metalloproteinase-9[21,22]. In the present study,
relative to the Weifuchun tablets the Weining Granules
were associated with significantly higher (P<0.05) rates
of: overall response (81.7% vs. 63.3% ); overall re-
sponse evaluated by gastroscopy (78.3% vs. 60.0% );
overall response (75.5% vs. 53.3% ) determined by
pathological examination; and cure (61.7% vs.
41.7%). This suggests that the Weining Granules had
superior efficacy in the treatment of GPLs relative to
the Weifuchun tablets.
HP is closely related to the occurrence of gastric carci-
noma. This disease when caused by chronic inflamma-
tion is an endogenous mutagenic source that induces
nitrite, which is a carcinogen. HP may also influence
the speed of epithelial proliferation due to a directly or
indirectly mediated immune inflammatory response.
Chronic HP infection may up-regulate the expression
of VEGF, induce neovascularization in gastric cancer
tissues and promote gastric oncogenesis. It has been
found that early eradication of HP was associated with
a reduction in the rate of gastric epithelial cell prolifera-
tion, significant delay in the development of precancer-
ous lesions and a reduced risk of gastric cancer[23-25]. In
the present study, we found that a significantly higher
proportion (75.0%) of patients receiving the Weining
Granules had their HP eradicated, as compared with
those (51.4% ) recieving the Weifuchun tablets (P<
0.05), suggesting that the Weining Granules had an in-
hibitory effect on HP.
Solid tumors are dependent on angiogenesis that is nec-
essary for their growth and metastasis. MVD has been
found to be an important biological parameter for eval-
uating the malignant level and outcome of tumors [26-27].
VEGF may specifically promote the following: endo-
thelial cell growth and angiogenesis; increased vascular
permeability; enhanced leakage of intravascular mass;
provision of matrixes for vascular endothelial cell mi-
gration and tumor cell metastasis; protection of vascu-
lar endothelial cells against apoptosis; promotion of di-
vision and proliferation of endothelial cells from differ-
ent sources, and vascular construction by inducing en-
dothelial cells to secrete various basement-mem-
brane-degrading enzymes resulting in the occurrence of
gastric cancer[28,29]. Our trial showed that the Weining
Granules were associated with significantly greater im-
provements in MVD and VEGF as compared with the
Weifuchun tablets (P<0.05 and P<0.01, respectively),
indicating that the Granules had a significantly higher
potential for improving angiogenesis.
It has been found that immune function is closely asso-
ciated with the occurrence of tumors and that the oc-
currence and development of gastric carcinoma is di-
rectly related to the anti-tumor immune function of
the host. Decreases in cellular immune function due to
various causes may lead to weakened immunologic sur-
veillance and an increased incidence of gastric cancer.
T cell function has a strong relationship with the occur-
rence and development of gastric cancer. The CD4 +/
CD8+ ratio better reflects the cellular immune function
and anti-tumor capacity of the host. IL-2 and IL-6 are
cytokines closely related to tumor cell growth. IL-2
may inhibit tumor growth by promoting the growth of
natural killer cells and the secretion of B cell immuno-
globulin, and by enhancing the anti-tumor activity of
T cells. As with β2-interferon, IL-6 may enhance the
antitumor activity of cytotoxic T-lymphocytes[30-32]. Our
study demonstrated that CD4+, CD4+/CD8+, IL-2, IL-6
and IgG were more significantly improved after treat-
ment with the Weining Granules than after treatment
with the Weifuchun tablets (P<0.05 or P<0.01), sug-
gesting the effectiveness of the Weining Granules in im-
proving immune function.
With paradigm changes in medical science and an up-
dated understanding of health, the patient's QOL mer-
its the same or greater attention than survival. QOL is
a composite indicator of physical and mental health, so-
cial adaptation and environment, which reflects the
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general well-being of individuals. This indicator is use-
ful for evaluating the impact of diseases and medical in-
terventions on patients, and also in relation to the phy-
sician's decision making process with regard to treat-
ment options[33]. In our trial, patients with GPLs who
had poor QOL experienced significantly greater bene-
fit in terms of physical, psychological and social rela-
tionships, and environment domains using the Wein-
ing Granules than using the Weifuchun tablets (P<
0.05 or P<0.01).
REFERENCES
1 Xu B, Wang JM. A study of gastric cancer epidemiology.
Chinese Journal of Cancer Prevention and Treatment
2006; 1: 1-4
2 Lu ZY, Zhong NS. Internal medicine. Beijing:People’s
Medical Publishing House; 2011: 397
3 Xie JR, Li W, Liu ZX, Wang JB. Clinical study of Weiling
granules on precancerous lesion in patients with chronic
atrophic gastritis. Chin J Integr Trad West Med Dig 2007;
15: 92-94
4 James Wall, MD, Jacques Marescaux, FRCS (Hon), JSES
(Hon). Robotic gastrectomy is safe and feasible, but real
benefits remain elusive Comment on "Robotic gastrecto-
my as an oncologically sound alternative to laparoscopic re-
sections for the treatment of early-stage gastric cancers".
Arch Surg 2011;146: 1092
5 Yanghee W, Woo JH, Kyung-Ho P, Kazuki I, Kazutaka O,
Seung HC, Sung HN. Robotic Gastrectomy as an Onco-
logically Sound Alternative to Laparoscopic Resections for
the Treatment of Early-Stage Gastric Cancers. Arch Surg
2011; 146: 1086-1092
6 Zhen XY. Guidance for clinical research of new traditional
Chinese drugs (tentative version). China Medical Science
Press 2002; 4: 125-129
7 Li YN, Xiao SD, Zhang JK. Diagnosis and treatment of
chronic gastritis. Chinese Journal of Internal Medicine
1983; 22: 261-262
8 Zhou JZ, Chen ZM, Wei BH. Diagnostic,syndrome dif-
ferentiation, and response criteria for chronic gastritis in
integrated chinese and western medicine (tentative ver-
sion). Chinese Journal of Integrated Traditional and West-
ern Medicine1990; 10: 318
9 Graziano Seghezzi, Sundeep Patel, Christine J, Gual-
andris A, Pintucci G, Robbins ES, Shapiro RL, Galloway
AC, Rifkin DB, Mignatti P. Fibroblast Growth Factor-2
(FGF-2) Induces vascular endothelial growth factor(vegf )
expression in the endothelial cells of forming capillaries:
an autocrine mechanism contributing to angiogenesis.
JCB Home 1998; 141: 1659-1673
10 WHO. World Health Organisation WHOQOL-BREF:
Introduction, Administration,Scoring and Generic Version
of the Assessment. Geneva 1996.
11 Hao YT, Fang JQ. Chinese version of WHOQOL:Intro-
duction and Administration. Modern Rehabilitation
2000; 4: 1123-1124
12 Chinese Society of Gastroenterology, Chinese Medical As-
sociation. Consensus on Helicobacter pylori (2003,
Tongcheng, Anhui). Chinese Journal of Digestion 2004;
24: 126
13 Zhen XY. Conducted in accordance with the Good Clini-
cal Practice (GCP). Chin J New Drugs Clin Rem 2004;
23: S1-S5
14 World Medical Association. World Medical Association
Declaration of Helsinki. JAMA 1997; 277: 925-926
15 Cai G. Experience in treating chronic atrophic gastritis
and its precancerous lesions. Jiangsu Journal of Traditional
Chinese Medicine 2007; 39: 1
16 Li Yan, Xu JK, Lu XR. Clinical and pathological research
of the treatment of gastric precancerous lesions by a gastri-
tis formula. Chinese Journal of Integrated Traditional and
Western Medicine 2011; 31: 1635-1638
17 Xie JR, Dai GL, Liang GY. Clinical study of Xinwei gran-
ules in treating of gastric precancerous lesion of Qi and
Yin deficiency with blood stagnation. Chinese Journal of
Integrated Traditional and Western Medicine on Digestion
2011; 19: 215-217
18 Liu QQ, Du YR, Su XL, Xiong P. Treatment of gastric pre-
cancerous lesions with the Dongxue detoxification and
blood-activating decoction: a report of 63 cases. Shaanxi
Journal of Traditional Chinese Medicine 2010; 31: 10-11
19 Cho WC, Leung KN. In vitro and in vivo anti-tumor ef-
fects of Astragalus membraneceus. Cancer Lett 2007; 252:
43
20 Qin B, Xie JX, Yang HL, Meifen Zhu, Hongyun Li, Yibin
Feng. Levels of curcumin in different processed products
of Guangxi native curcuma and its in vivo anti-tumor ac-
tivity. Journal of Chinese Medicinal Materials 2010; 33:
1379-1382
21 Liang J, Deng X, Huang RB. Effects of "Weining Decoc-
tion" on proliferation and apoptosis of human gastric can-
cer SGC-7910 cells. Shanghai Journal of Traditional Chi-
nese Medicine 2006; 40: 66-68
22 Liang J, Deng X, Huang RB. Effects of "Weining Decoc-
tion" on human gastric cancer cell invasiveness. Liaoning
Journal of Traditional Chinese Medicine 2006; 33:
899-900
23 Wu Y, Li X, Zhou H, Yu Fan, You-Li Zhang, Yan Shen,
He YL. Effect of H.pylori extract on cellular morphology
and apoptosis-related gene expression in human gastric
cancer BGC-823 cells. World Chinese Journal of Digestol-
ogy 2011; 19: 1767-1772
24 Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Wata-
nabe M, Ito S, Sawaki A, Iida S,Sato S, Yatabe Y, Yamao
K, Ueda R, Tajima K, Hamajima N, Tanaka H. ABO Gen-
otype and the Risk of Gastric Cancer, Atrophic Gastritis,
and Helicobacter pylori Infection. Cancer Epidemiol Bio-
markers Prev 2011; 20: 1665-1672
25 Kang S, Choi J, Ahn M, Lee HW, Jeong SH, Park JS,
Cho YK, Han SU, Kim YB, Kim JH, Sheen SS, Lim HY,
Choi JH. Helicobacter pylori infection as an independent
prognostic factor for locally advanced gastric cancer with
curative resection. J Clin Oncol 2010; 28: 4121
26 Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J,
Strommer S, Wacheck V. mTOR Inhibition Sensitizes Gas-
tric Cancer to Alkylating Chemotherapy In Vivo. Antican-
cer Research 2008; 28: 3801-3808
171
JTCM |www. journaltcm. com June 15, 2012 |volume 32 | Issue 2 |
Deng X et al. A clinical study ofWeining granules in the treatment of gastric precancerous lesions
27 Lee BL, Kim WH, Jung J, Cho SJ, Park JW, Kim J,
Chung HY, Chang MS, Nam SY. A hypoxia-independent
up-regulation of hypoxia-inducible factor-1 by AKT con-
tributes to angiogenesis in human gastric cancer. Carcino-
genesis 2008; 29: 44-51
28 Ho CC, Lai KC, Kuo CL, Ma CY, Lin ML, Yang JS,
Chung JG. Benzyl isothiocyanate (BITC) inhibits migra-
tion and invasion of human gastric cancer AGS cells via
suppressing ERK signal pathways. Hum Exp Toxicol
2011; 30: 296-306
29 Yang MD, Lai KC, Lai TY, Hsu SC, Kuo CL, Yu CS, Lin
ML, Yang JS, Kuo HM, Wu SH, Chung JG. Phenethyl
isothiocyanate inhibits migration and invasion of human
gastric cancer AGS cells through suppressing MAPK and
NF-κB signal pathways. Anticancer Research 2010; 30:
2135-2143
30 Chen G, Zhang FJ, Gong M, Yan M. Effect of periopera-
tive autologous versus allogeneic blood transfusion on the
immune system in gastric cancer patients. J Zhejiang Univ
Sci B 2007; 8: 560-565
31 Yan LL, Yu GW, Yong QW, Li Z, Wang RC, Wang L,
Zhang YY. Bone marrow-derived dendritic cells pulsed
with tumor lysates induce anti-tumor immunity against
gastric cancer exvivo. World J Gastroenterol 2008; 14:
7127-7132
32 YMitsushige Sugimoto, Yoshio Yamaoka, Takahisa Furu-
ta. Influence of interleukin polymorphisms on develop-
ment of gastric cancer and peptic ulcer. World J Gastroen-
terol 2010; 16: 1188-1200
33 Yoon SJ, Heo DS, Kang SH, Lee KH, Kim WS, Kim GP,
Lee JA, Lee KS, Bang YJ, Kim NK. Natural killer cell ac-
tivity depression in peripheral blood and ascites from gas-
tric cancer patients with high TGF-beta (1) expression. An-
ticancer Res 1998; 18: 1591-1596
172
